NCT05903040Completed
Ditan Acute tReatments: Effectiveness and Tolerability (DART)
Effectiveness and Tolerability of Lasmiditan as Acute Migraine Treatment: a Prospective, Multicentric, Cohort Study
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of lasmiditan as acute migraine treatment in a cohort of episodic or chronic migraine patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 100 (actual)
- First submitted
- 5 Jun 2023
- Start date
- 15 Jun 2023
- Primary completion date
- 1 Jun 2024
- Lead sponsor
- University of Florence
- Diseases
- Migraine
- NCT number
- NCT05903040
What you commit to
- Study type: Observational
- Participants enrolled: 100
- From 15 Jun 2023 to the primary completion date, 1 Jun 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
Other
- Subjects with contraindications for use of ditans;
- medical comorbidities that could interfere with study results;
- Pregnancy and breastfeeding.
Who the study is looking for
- Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III).
- At least 3 MMDs
- Good compliance to study procedures
- Availability of headache diary at least of the preceding months before enrollment
Age in the registry: 18 years to - · Sex: All
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi Coordinator of this site? Confirm its status | Florence | Italy | Unknown status |
| IRCCS National Neurological Institute "C. Mondino" Foundation Coordinator of this site? Confirm its status | Pavia | Italy | Unknown status |
Related publications
- Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study).Ther Adv Neurol Disord · 2025 · PMID 41446321
This page is information, not medical advice. Discuss any trial with your doctor.